Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1960 2
1961 1
1962 3
1963 10
1964 12
1965 10
1966 7
1967 6
1968 20
1969 27
1970 16
1971 28
1972 29
1973 12
1974 13
1975 15
1976 19
1977 28
1978 34
1979 30
1980 24
1981 17
1982 11
1983 26
1984 25
1985 17
1986 18
1987 29
1988 27
1989 29
1990 28
1991 50
1992 41
1993 48
1994 51
1995 76
1996 100
1997 97
1998 145
1999 191
2000 202
2001 224
2002 330
2003 373
2004 409
2005 484
2006 588
2007 652
2008 725
2009 804
2010 980
2011 1113
2012 1306
2013 1452
2014 1764
2015 1886
2016 1980
2017 2100
2018 2226
2019 2337
2020 2745
2021 2922
2022 2710
2023 2620
2024 1122

Text availability

Article attribute

Article type

Publication date

Search Results

31,685 results

Results by year

Filters applied: . Clear all
Page 1
Understanding and overcoming metformin gastrointestinal intolerance.
Bonnet F, Scheen A. Bonnet F, et al. Diabetes Obes Metab. 2017 Apr;19(4):473-481. doi: 10.1111/dom.12854. Epub 2017 Feb 22. Diabetes Obes Metab. 2017. PMID: 27987248 Review.
Although starting at a low dose and titrating slowly may help prevent some GI AEs associated with metformin, some patients are unable to tolerate metformin at all and it may also be difficult to convince patients to start metformin again after a bout of GI AE …
Although starting at a low dose and titrating slowly may help prevent some GI AEs associated with metformin, some patients are unable …
Metformin: Is it a drug for all reasons and diseases?
Triggle CR, Mohammed I, Bshesh K, Marei I, Ye K, Ding H, MacDonald R, Hollenberg MD, Hill MA. Triggle CR, et al. Metabolism. 2022 Aug;133:155223. doi: 10.1016/j.metabol.2022.155223. Epub 2022 May 29. Metabolism. 2022. PMID: 35640743 Free article. Review.
In type 1 diabetes metformin may help reduce the insulin dose. Meta-analysis and data from pre-clinical and clinical studies link metformin to a reduction in the incidence of cancer. Clinical trials, including MILES (Metformin In Longevity Study), and TAME (T …
In type 1 diabetes metformin may help reduce the insulin dose. Meta-analysis and data from pre-clinical and clinical studies link …
A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan.
Mohammed I, Hollenberg MD, Ding H, Triggle CR. Mohammed I, et al. Front Endocrinol (Lausanne). 2021 Aug 5;12:718942. doi: 10.3389/fendo.2021.718942. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34421827 Free PMC article. Review.
Indeed, clinical trials, including the MILES (Metformin In Longevity Study) and TAME (Targeting Aging with Metformin), have been designed to assess the potential benefits of metformin as an anti-aging drug. Preliminary analysis of results from MILES indicate …
Indeed, clinical trials, including the MILES (Metformin In Longevity Study) and TAME (Targeting Aging with Metformin), have be …
Metformin-associated lactic acidosis: Current perspectives on causes and risk.
DeFronzo R, Fleming GA, Chen K, Bicsak TA. DeFronzo R, et al. Metabolism. 2016 Feb;65(2):20-9. doi: 10.1016/j.metabol.2015.10.014. Epub 2015 Oct 9. Metabolism. 2016. PMID: 26773926 Free article. Review.
Elevated plasma metformin concentrations (as occur in individuals with renal impairment) and a secondary event or condition that further disrupts lactate production or clearance (e.g., cirrhosis, sepsis, or hypoperfusion), are typically necessary to cause metformin- …
Elevated plasma metformin concentrations (as occur in individuals with renal impairment) and a secondary event or condition that furt …
Metformin and Systemic Metabolism.
He L. He L. Trends Pharmacol Sci. 2020 Nov;41(11):868-881. doi: 10.1016/j.tips.2020.09.001. Epub 2020 Sep 28. Trends Pharmacol Sci. 2020. PMID: 32994049 Free PMC article. Review.
Metformin can improve patients' hyperglycemia through significant suppression of hepatic glucose production. ...These metformin effects result in the improvement of insulin sensitivity and glucose utilization in extrahepatic tissues. ...
Metformin can improve patients' hyperglycemia through significant suppression of hepatic glucose production. ...These metformin …
Metformin and the gastrointestinal tract.
McCreight LJ, Bailey CJ, Pearson ER. McCreight LJ, et al. Diabetologia. 2016 Mar;59(3):426-35. doi: 10.1007/s00125-015-3844-9. Epub 2016 Jan 16. Diabetologia. 2016. PMID: 26780750 Free PMC article. Review.
A novel delayed-release preparation of metformin has recently been shown to improve glycaemic control to a similar extent to immediate-release metformin, but with less systemic exposure. ...This review examines the passage of metformin through the gut, and ho …
A novel delayed-release preparation of metformin has recently been shown to improve glycaemic control to a similar extent to immediat …
Metformin: historical overview.
Bailey CJ. Bailey CJ. Diabetologia. 2017 Sep;60(9):1566-1576. doi: 10.1007/s00125-017-4318-z. Epub 2017 Aug 3. Diabetologia. 2017. PMID: 28776081
Metformin (dimethylbiguanide) has become the preferred first-line oral blood glucose-lowering agent to manage type 2 diabetes. ...Long-term cardiovascular benefits of metformin were identified by the UK Prospective Diabetes Study (UKPDS) in 1998, providing a new rat …
Metformin (dimethylbiguanide) has become the preferred first-line oral blood glucose-lowering agent to manage type 2 diabetes. ...Lon …
The effects of metformin on autophagy.
Lu G, Wu Z, Shang J, Xie Z, Chen C, Zhang C. Lu G, et al. Biomed Pharmacother. 2021 May;137:111286. doi: 10.1016/j.biopha.2021.111286. Epub 2021 Jan 30. Biomed Pharmacother. 2021. PMID: 33524789 Free article. Review.
However, the mechanisms of metformin actions were not fully illuminated. Recently, increasing researches showed that autophagy is a vital medium of metformin playing pharmacological actions. ...The pharmacological effects of metformin combining its actions on …
However, the mechanisms of metformin actions were not fully illuminated. Recently, increasing researches showed that autophagy is a v …
A review of phenformin, metformin, and imeglimin.
Yendapally R, Sikazwe D, Kim SS, Ramsinghani S, Fraser-Spears R, Witte AP, La-Viola B. Yendapally R, et al. Drug Dev Res. 2020 Jun;81(4):390-401. doi: 10.1002/ddr.21636. Epub 2020 Jan 9. Drug Dev Res. 2020. PMID: 31916629 Review.
Metformin is administered orally and has desirable pharmacokinetics. ...However, like metformin, imeglimin is also a basic small molecule. Imeglimin is synthesized from metformin as a precursor via a single step chemical reaction. ...
Metformin is administered orally and has desirable pharmacokinetics. ...However, like metformin, imeglimin is also a basic sma …
Metformin - a new approach.
Cwynar-Zając Ł. Cwynar-Zając Ł. Pediatr Endocrinol Diabetes Metab. 2021;27(2):134-140. doi: 10.5114/pedm.2021.107166. Pediatr Endocrinol Diabetes Metab. 2021. PMID: 34514769 Free PMC article. Review.
Currently, metformin is used not only in the treatment of diabetes but also in other diseases. ...Longer survival times have been observed in cancer patients using metformin. Metformin has been shown to significantly correlate with lower mortality in obese or …
Currently, metformin is used not only in the treatment of diabetes but also in other diseases. ...Longer survival times have been obs …
31,685 results
You have reached the last available page of results. Please see the User Guide for more information.